4 Biotechs Facing Do-or-Die Catalysts in December Post author:Sam Post published:December 5, 2017 Post category:BioPharma As 2018 winds down, it’s not over for some biopharma companies. Source: BioSpace You Might Also Like FDA Raises Big Safety Concerns With Johnson & Johnson's Arthritis Drug Sirukumab July 30, 2017 Sanofi: Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function i… October 30, 2017 What You Need to Know About Corbin Therapeutics January 14, 2018
Sanofi: Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function i… October 30, 2017
